Filing Flows › Karyopharm Therapeutics (KPTI) › Q1 2026
Karyopharm Therapeutics (KPTI) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 14, 2026
Karyopharm Therapeutics (KPTI) reported revenue of $35.1M for the first quarter 2026 (Q1 2026), +17% from a year earlier and +3% from the quarter before. Operating margin was -76.3%, net loss $22.4M (63.9% of revenue).
Karyopharm Therapeutics, Q1 2026: revenue $35.1M (+17% year over year), operating margin -76.3%, net loss $22.4M, operating cash flow −$22.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $35.1M | +3% | +17% |
| Operating profit | −$26.8M | — | — |
| Net earnings | −$22.4M | — | — |
| Operating cash flow | −$22.7M | — | — |
What changed
Revenue was $35.1M in Q1 2026, up 17% year over year and up 3% from the previous quarter. Product was the largest line at 83% of revenue. Product added $8.1M year over year (up 39%), 161% of the total change. License and Other declined 34%.
Operating costs exceeded revenue by $26.8M, an operating margin of -76.3%. Total costs fell 2% while revenue rose 17%. The quarter ended with a net loss of $22.4M, narrower than the previous quarter's $102.2M loss.
Operating cash flow was −$22.7M. Non-cash charges added back $12K of depreciation and $3.0M of share-based compensation. Working capital and other items used $3.4M.
Questions
What was Karyopharm Therapeutics' revenue in the first quarter 2026?
Karyopharm Therapeutics (KPTI) reported revenue of $35.1M for the first quarter 2026 (Q1 2026), +17% from a year earlier and +3% from the quarter before.
Was Karyopharm Therapeutics profitable in the first quarter 2026?
Operating loss was $26.8M (-76.3% of revenue) and net loss $22.4M.